海翔药业(002099) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was ¥610,754,044.64, representing a 4.54% increase compared to ¥584,239,451.12 in the same period last year[8]. - The net profit attributable to shareholders decreased by 61.51% to ¥44,768,449.76 from ¥116,313,042.33 year-on-year[8]. - The net profit after deducting non-recurring gains and losses also fell by 61.78%, amounting to ¥43,780,799.03 compared to ¥114,535,120.43 in the previous year[8]. - Basic and diluted earnings per share dropped by 57.14% to ¥0.03 from ¥0.07 year-on-year[8]. - The weighted average return on equity decreased by 1.54 percentage points to 0.87% from 2.41% in the previous year[8]. - The company expects net profit attributable to shareholders for the first half of 2018 to decline by 10.00% to 60.00% compared to the same period in 2017[20]. - The anticipated net profit range for the first half of 2018 is between CNY 9,738.42 million and CNY 21,911.46 million[20]. Cash Flow and Assets - The net cash flow from operating activities increased by 38.78% to ¥161,505,950.17, up from ¥116,376,241.70 in the same period last year[8]. - Total assets at the end of the reporting period were ¥7,159,190,218.04, a decrease of 4.12% from ¥7,466,927,438.54 at the end of the previous year[8]. - The net assets attributable to shareholders increased by 1.08% to ¥5,197,538,406.10 from ¥5,142,008,176.75 at the end of the previous year[8]. - Cash flow from operating activities increased by 38.78% to CNY 161,505,950.17, driven by the collection of acceptance bills and recovery of pledged deposits[16]. - Cash flow from investing activities improved by 247.48% to CNY 8,294,108.93, mainly due to the maturity of financial products[16]. - Cash flow from financing activities decreased significantly by 1138.16% to a net outflow of CNY 303,057,413.22, primarily due to loan repayments[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 60,905[12]. - The company plans to repurchase shares with a total amount not exceeding CNY 30 million at a price not exceeding CNY 7 per share[17]. Non-Recurring Gains and Expenses - The company reported non-recurring gains of ¥987,650.73, primarily from government subsidies and other income[9]. - Prepayments increased by 52.89% to CNY 86,358,956.19 due to advance payments for raw materials[16]. - Other receivables surged by 337.81% to CNY 14,614,863.53 primarily due to an increase in temporary payments receivable[16]. - Financial expenses rose by 442.03% to CNY 84,704,153.96, mainly due to increased exchange losses from the appreciation of the RMB against the USD[16]. - Investment income decreased by 518.00% to a loss of CNY 5,810,881.16, attributed to foreign exchange losses from currency swap transactions[16].